vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.
Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.7M, roughly 1.4× PureCycle Technologies, Inc.).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.
IRD vs PCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.7M |
| Net Profit | — | $-18.8M |
| Gross Margin | — | — |
| Operating Margin | — | -2196.1% |
| Net Margin | — | -697.1% |
| Revenue YoY | -10.2% | — |
| Net Profit YoY | 53.0% | 71.0% |
| EPS (diluted) | — | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.7M | ||
| Q3 25 | $3.1M | $2.4M | ||
| Q2 25 | $2.9M | $1.6M | ||
| Q1 25 | $4.4M | $1.6M | ||
| Q4 24 | $4.3M | $0 | ||
| Q3 24 | $3.9M | $0 | ||
| Q2 24 | $1.1M | $0 | ||
| Q1 24 | $1.7M | $0 |
| Q4 25 | — | $-18.8M | ||
| Q3 25 | $-17.5M | $-28.4M | ||
| Q2 25 | $-7.4M | $-144.2M | ||
| Q1 25 | $-8.2M | $8.8M | ||
| Q4 24 | — | $-64.7M | ||
| Q3 24 | $-7.5M | $-90.6M | ||
| Q2 24 | $-7.8M | $-48.2M | ||
| Q1 24 | $-7.1M | $-85.6M |
| Q4 25 | — | -2196.1% | ||
| Q3 25 | -269.9% | -1602.2% | ||
| Q2 25 | -309.0% | -2763.5% | ||
| Q1 25 | -227.2% | -2387.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -207.1% | — | ||
| Q2 24 | -748.9% | — | ||
| Q1 24 | -450.5% | — |
| Q4 25 | — | -697.1% | ||
| Q3 25 | -566.9% | -1167.5% | ||
| Q2 25 | -257.5% | -8741.8% | ||
| Q1 25 | -187.5% | 559.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -194.6% | — | ||
| Q2 24 | -698.3% | — | ||
| Q1 24 | -415.3% | — |
| Q4 25 | — | $-0.14 | ||
| Q3 25 | $-0.25 | $-0.31 | ||
| Q2 25 | $-0.12 | $-0.81 | ||
| Q1 25 | $-0.24 | $0.05 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | $-0.29 | $-0.54 | ||
| Q2 24 | $-0.30 | $-0.29 | ||
| Q1 24 | $-0.29 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $156.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $45.9M |
| Total Assets | $50.2M | $922.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $156.7M | ||
| Q3 25 | $30.8M | $234.4M | ||
| Q2 25 | $32.4M | $284.1M | ||
| Q1 25 | $41.8M | $22.5M | ||
| Q4 24 | $30.3M | $15.7M | ||
| Q3 24 | $36.6M | $83.7M | ||
| Q2 24 | $41.4M | $10.9M | ||
| Q1 24 | $47.2M | $25.0M |
| Q4 25 | $15.3M | $45.9M | ||
| Q3 25 | $6.0M | $68.2M | ||
| Q2 25 | $17.5M | $98.9M | ||
| Q1 25 | $5.1M | $238.2M | ||
| Q4 24 | $6.7M | $180.4M | ||
| Q3 24 | $34.3M | $241.4M | ||
| Q2 24 | $40.6M | $291.6M | ||
| Q1 24 | $46.1M | $336.8M |
| Q4 25 | $50.2M | $922.7M | ||
| Q3 25 | $36.1M | $989.1M | ||
| Q2 25 | $38.7M | $1.0B | ||
| Q1 25 | $48.2M | $787.3M | ||
| Q4 24 | $36.9M | $798.4M | ||
| Q3 24 | $40.4M | $788.8M | ||
| Q2 24 | $44.8M | $719.8M | ||
| Q1 24 | $51.8M | $734.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-28.7M |
| Free Cash FlowOCF − Capex | — | $-42.0M |
| FCF MarginFCF / Revenue | — | -1559.6% |
| Capex IntensityCapex / Revenue | — | 495.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-183.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-28.7M | ||
| Q3 25 | $-6.2M | $-38.5M | ||
| Q2 25 | $-10.3M | $-36.7M | ||
| Q1 25 | $-9.0M | $-38.9M | ||
| Q4 24 | $-25.6M | $-31.8M | ||
| Q3 24 | $-5.1M | $-33.4M | ||
| Q2 24 | $-7.3M | $-40.4M | ||
| Q1 24 | $-5.7M | $-39.2M |
| Q4 25 | — | $-42.0M | ||
| Q3 25 | — | $-42.4M | ||
| Q2 25 | — | $-45.3M | ||
| Q1 25 | — | $-53.9M | ||
| Q4 24 | — | $-53.4M | ||
| Q3 24 | — | $-42.6M | ||
| Q2 24 | — | $-50.8M | ||
| Q1 24 | — | $-53.5M |
| Q4 25 | — | -1559.6% | ||
| Q3 25 | — | -1743.1% | ||
| Q2 25 | — | -2747.1% | ||
| Q1 25 | — | -3409.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 495.1% | ||
| Q3 25 | — | 160.3% | ||
| Q2 25 | — | 521.5% | ||
| Q1 25 | — | 949.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
